Laurence Ion and Niklas Anzinger will lead different ventures focusing on regulatory zones and scaling and accelerating innovation.
Laurence Ion and Niklas Anzinger, co-founders of Vitalia, have announced they are separating their efforts into two distinct ventures in a move that aims to best fulfill their respective visions for advancing biomedical innovation through regulatory frameworks. While Ion will head Viva City, focused on establishing a city governed by its residents to foster medical progress, Anzinger will lead Infinita City, emphasizing regulatory zones as a pathway to broader acceleration, and Infinita will continue with the same team, partnerships and plans as announced prior under Vitalia‘s banner. Both initiatives maintain a shared commitment to extending healthy human lifespan.
Longevity.Technology: The emergence of Viva City and Infinita City reflects two different approaches to advancing longevity therapeutics. By pursuing separate but complementary paths, these ventures reflect the importance of tailored strategies for regulatory environments; fostering innovation in medical science requires both experimental local governance models and scalable frameworks. Such dual approaches may provide a robust platform for longevity solutions to thrive, and parallel development in regulatory innovation could potentially accelerate the path to more effective and efficient approval processes for healthspan and longevity therapeutics.
Viva City and its resident-led model
Laurence Ion’s Viva City aims to establish a city operating within a special regulatory zone that will grant its residents a degree of governance autonomy to facilitate medical innovation. According to the announcement, the initiative seeks to create an environment conducive to breakthroughs in healthcare, with a clear focus on accelerating the extension of healthy lifespans.
This novel governance model aims to empower residents, enabling a collaborative approach to addressing the challenges and opportunities presented by longevity science, and the venture hopes to align innovative medical research with resident-driven regulatory policies.
Infinita City and its scalable vision
Niklas Anzinger’s Infinita City will channel its efforts into leveraging special regulatory zones as a mechanism for accelerating biomedical progress. Unlike Viva City’s resident-focused governance, Infinita aims to create scalable regulatory solutions that could be applied to multiple jurisdictions. Infinita, which has $10 million in investment and an ongoing popup city with approximately 700 people expected in the next few months, seeks to optimize conditions for rapid advancements in medical research while maintaining adaptability to diverse regulatory landscapes. By prioritizing frameworks that can extend beyond individual projects, Infinita positions itself as a driver of systemic change in how innovation is regulated and implemented. Infinita has also established a new clinic and a new academic program to build foundational institutions for a lasting city development for biomedical acceleration.
The ground operations in Próspera ZEDE that Vitalia established will continue under Infinita.
A shared legacy and distinct futures
In a statement, the founders emphasized that their time at Vitalia had created a shared legacy. “Together, we built Vitalia from the ground up, establishing a foundation that has led us to this exciting new chapter,” they said, adding that the decision reflects their shared recognition that their unique perspectives are best realized through separate organizations, each pursuing its vision independently while remaining complementary in their goals.
Both Ion and Anzinger acknowledged the contributions of the wider community. “We extend our gratitude to our community, partners, and investors, whose trust has been pivotal,” they said. “Vitalia will forever continue in our shared memory.”
